ArticleScientific reports2025
Understanding individual neurodegenerative progression in Parkinson's disease through normative modelling.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genetic Associations with Temporal Modeling of Alzheimer's Disease Progression Supports a Novel Paradigm for Disease Risk.medRxiv : the preprint server for health sciences · 2026Article
- [Research progress on intelligent brain age prediction methods in diagnosis of Parkinson's disease].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026Review
- Sense of agency and decision making.Frontiers in psychology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Parkinson's disease (PD) is a neurodegenerative disorder with motor symptoms (e.g., bradykinesia, tremors) and non-motor symptoms (e.g., cognitive deficits). Symptom progression varies across individuals, possibly due to differences in the spread of disease pathology. This study investigates individual-level gray matter atrophy in PD patients compared to a reference cohort, modeling neurobiological trajectories to understand symptom progression. Using normative modeling, we mapped individual deviations in gray matter atrophy in PD patients (Personalized Parkinson Project, PPP; N = 408; 42% female) against a reference model (N = 58, 836) of non-diagnosed individuals. Gray matter atrophy was defined as negative deviations from the normative model in cortical thickness and subcortical volume at baseline and two-year follow-up. We correlated the deviations with clinical motor and cognitive symptoms at an individual level and compared changes across PD subtypes (mild-motor predominant, intermediate, and diffuse-malignant). Cross-sectionally, PD patients showed significant gray matter atrophy, which correlated with cognitive impairment. Longitudinally, cortical thinning and subcortical atrophy patterns showed variation amongst subtypes. Specifically, the diffuse-malignant subtype, which is characterized by more diffuse symptoms and faster clinical progression, exhibited pronounced cortical thinning and subcortical atrophy over time. In this paper, we have considered the deviation scores at three levels of granularity: cases vs. control, subtypes, and the individual level. While our findings show subgroup-level patterns of variability, they also provide a method for exploring individual-level metrics of disease progression, acknowledging that individuals may deviate from the predefined categories or groups and can exhibit large variability over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.